ClinicalTrials.gg
RecruitingNCT05420493Updated Jan 5, 2024

Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma

A Phase 1 interventional study of CAR-T cells in Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma and Non Hodgkin Lymphoma, sponsored by Chongqing Precision Biotech Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-05.

Sponsored by Chongqing Precision Biotech Co., Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 1 month ago, but the record still lists the study as recruiting.
  • Registered 9 months after the study started (first participant enrolled Sep 2021, registered Jun 2022).
  • Started Sep 2021; still recruiting 5 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 196 studies in Lymphoma, Non-Hodgkin with a site in China — 83 open to participants now, 110 under way, 14 of them phase 3. Lymphoma, Non-Hodgkin · China.

Planned enrollment
94th of 183
54 · median 58
Started
2021
with 19 others
Phase 1
79 of 196
33 open now
Primary completion
2024-09
later than 21 of 109 live
Registered
122nd of 196
by date

Among the 196 studies in Lymphoma, Non-Hodgkin with a site in China, this one is the 94th largest by planned enrollment of the 183 interventional ones that give a count, is one of 20 that started in 2021, is one of 79 in phase 1, reaches primary completion later than 21 of the 109 other live ones, and was the 122nd registered.

Lymphoma, Non-Hodgkin

2,288 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

83 of the 196 studies in Lymphoma, Non-Hodgkin with a site in China are open now. Recruiting first, the newest first:

78 more — sign in →

All 83 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 196 studies in Lymphoma, Non-Hodgkin with a site in China, or all of them as a file.
02

Study summary

This is a phase I clinical study to evaluate the safety and efficacy of CAR-T infusion preparation in the treatment of CD19-positive relapsed/refractory non-Hodgkin lymphoma.

Read the detailed description

This is a single-center, single-arm, open-label study. After meeting the eligibility criteria and enrolling on the trial, patients will undergo leukapheresis for collection of autologous lymphocytes. Once cells have been manufactured, patients will then proceed to lymphodepleting chemotherapy with cyclophosphamide and fludarabine for 1-2 consecutive days followed by the infusion of CAR T-cells at a target dose of 3-10x105 cells/kg.

03

Conditions studied

  • Relapsed Non-Hodgkin Lymphoma
  • Refractory Non-Hodgkin Lymphoma
  • Non Hodgkin Lymphoma

Keywords

  • CAR-T
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. CD19-positive non-Hodgkin lymphoma confirmed by cytology or histology according to WHO2016 criteria:

    1. Diffuse large B-cell lymphoma: including unspecified (DLBCL, NOS), chronic inflammation-related DLBCL, primary cutaneous DLBCL (leg type), EBV-positive DLBCL (NOS); and high-grade B-cell lymphoma (including high-grade B-cell lymphoma, NOS, and high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements); and primary mediastinal large B-cell lymphoma; and T-cell-rich histiocytosis B-cell lymphoma; and transformed DLBCL (such as follicular lymphoma, chronic lymphocytic leukemia/small B-lymphocytic lymphoma transformed DLBCL); patients with the above tumor types have been treated with at least first- and drugs and have stable disease for ≤12 months , or when the best Disease progression after efficacy; or disease progression or relapse after stem cell transplantation ≤12 months;
    2. According to WHO2016 criteria cytology or histology confirmed CD19 positive: follicular cell lymphoma. Patients with this tumor type have received at least third-line therapy, and recurrence or disease progression has occurred within 2 years after third-line therapy or more. Currently in disease progression, stable disease, or partial remission;
    3. According to WHO2016 standard cytology or histology confirmed CD19 positive: mantle cell lymphoma. Such patients have not been cured or after at least three-line treatment and are not suitable for stem cell transplantation or relapse after stem cell transplantation;
  2. Age ≥18 years old (including the threshold);
  3. According to the 2014 version of Lugano criteria, there is at least one two-dimensional as the evaluation basis: for intranodal lesions, it is defined as: long diameter >1.5cm; for extranodal lesions, long diameter should be >1.0cm;
  4. activity status score ECOG score 0-2;
  5. The venous access required for collection can be established, and there are enough cells collected by non-mobilized apheresis for CAR-T cell production;
  6. Liver and kidney function, cardiopulmonary function meet the following requirements:

    • Serum creatinine≤2.0×;
    • ≥ 50% and no obvious pericardial effusion, no abnormal ;
    • Blood oxygen saturation ≥92% in non-oxygen state;
    • Blood total ≤2.0×ULN (except without clinical significance);
    • and AST≤3.0×ULN (with liver tumor infiltration≤5.0×ULN);
  7. Be able to understand and voluntarily sign the .

Exclusion criteria

Exclusion Criteria:

  1. Received CAR-T therapy or other gene-modified cell therapy before screening;
  2. Received anti-tumor therapy (except systemic immune checkpoint inhibition or stimulation therapy) within 2 weeks or 5 half-lives (whichever is shorter) before screening. 3 half-lives are required to enroll (eg, ipilimumab, nivolumab, pembrolizumab, atezolizumab, OX40 receptor agonist, 4-1BB receptor agonist, etc.);
  3. Those who have received hematopoietic stem cell transplantation () within 12 weeks before apheresis, or who have previously received allogeneic hematopoietic stem cell transplantation (HSCT), or those who have solid organ transplantation; is required within 2 weeks before apheresis Grade 2 and above of the drug;
  4. Patients with atrial or ventricular lymphoma involvement or need urgent treatment due to tumor mass such as intestinal obstruction or vascular compression;
  5. Have been vaccinated with within 6 weeks before clearing the leprosy;
  6. Cerebrovascular accident or epilepsy occurred within 6 months before signing the ICF;
  7. History of myocardial infarction, cardiac bypass or stent, unstable angina or other heart disease within 12 months prior to signing the ICF;
  8. Active or uncontrolled diseases (such as Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus), except those that do not require systemic treatment;
  9. Malignant tumors other than non-Hodgkin lymphoma within 5 years prior to screening, except for adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, localized prostate cancer after radical resection, Ductal carcinoma in situ;
  10. Uncontrollable infection within 1 week before screening;
  11. surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive and peripheral blood hepatitis B virus (HBV) DNA titer detection is greater than the normal reference range; or virus (HCV) antibody positive and peripheral blood C Hepatitis virus (HCV) RNA titer test is greater than the normal reference range; or (HIV) antibody positive; or syphilis test positive; cytomegalovirus (CMV) DNA test positive;
  12. Women who are pregnant or breastfeeding; or women of childbearing age who have a positive pregnancy test during the screening period; or male or female patients who are unwilling to use from the time of signing the form to 1 year after receiving CAR-T cell infusion;
  13. Other investigators deem it inappropriate to participate in the study.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    Intravenous of CAR-T

    Infusion of CAR-T cells by dose of 3-10 x105 cells/kg

    Biological: CAR-T cells

Interventions

  • BiologicalCAR-T cells

    Drug: CAR-T cells; Administration method: intravenous infusion; Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse events after CAR-T cells infusion [Safety and Tolerability]

    Therapy-related adverse events were recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0)

    Time frame: 28 days

  2. Objective response rate after CAR-T cells infusion [Effectiveness]

    Objective response rate includes CR,PR

    Time frame: 3 months

Secondary outcomes

  1. AUCS of CAR-T cells [Cell dynamics]

    AUCS is defined as the area under the curve in 90 days

    Time frame: 3 months

  2. CMAX of pCAR-19B cells [Cell dynamics]

    CMAX is defined as the highest concentration of pCAR-19B cells expanded in peripheral blood

    Time frame: 3 months

  3. TMAX of pCAR-19B cells [Cell dynamics]

    TMAX is defined as the time to reach the highest concentration

    Time frame: 3 months

  4. Pharmacodynamics of pCAR-19B cells[Cell dynamics]

    IL-6 levels measured by Chemiluminescence method

    Time frame: 3 months

Other outcomes

  1. Objective response rate (ORR) of CAR-T treatment in patients with Relapsed/refractory B-cell non-Hodgkin lymphoma[Effectiveness]

    Objective response rate includes:CR、PR

    Time frame: 2 years

  2. Overall survival(OS)of CAR-T treatment in patients with Relapsed/refractory B-cell non-Hodgkin lymphoma[Effectiveness]

    OS will be assessed from the first CAR-T cell infusion to death from any cause

    Time frame: 2 years

  3. Progress-free survival(PFS) of CAR-T treatment in patients with Relapsed/refractory B-cell non-Hodgkin lymphoma[Effectiveness]

    PFS will be assessed from the first CAR-T cell infusion to death from any cause or the first assessment of progression

    Time frame: 2 years

  4. Duration of Response (DOR) of CAR-T treatment in patients with Relapsed/refractory B-cell non-Hodgkin lymphoma[Effectiveness]

    DOR will be assessed from the first assessment of CR/PR to the first assessment of recurrence or progression of the disease or death from any cause

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2021 (actual). Primary completion is estimated for Sep 2024, 36 months after the start.

Of 163 industry-sponsored phase 1 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 70. This study's planned 36 months is below that.

Counting every sponsor, half of 286 studies reached it within 55 months; a quarter within 38 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2022
First posted
Jun 15, 2022
StartActual
Sep 6, 2021
Primary completionEst.
Sep 30, 2024
CompletionEst.
Sep 30, 2025
Last update
Jan 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05420493
Responsible party
Sponsor
First posted
Jun 15, 2022
Start date
Sep 6, 2021
Primary completion
Sep 30, 2024 (estimated)
Completion
Sep 30, 2025 (estimated)
Last update
Jan 5, 2024

Study contacts

Jingwang Bi, M.D
Contact
jingwangbi@live.cn
13066029387
Jianfeng Bi, M.D
principal investigator · Shandong Second Provincial General Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chimeric Antigen Receptor T-cells

Start the discussion